Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?
This article was originally published in PharmAsia News
Executive Summary
The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence
You may also be interested in...
EFPIA Hopes To Shift Conversation In Japan From Pricing To Funding
The European pharma trade group also plans communication offensive on health technology assessment as Japan reconsiders pricing methodology.
Japan 2012 NHI Price Revision Takes Shape, Long-Listed Products See Smaller Cuts Than Expected
Japan's MHLW and Finance Ministry face off on the steps needed to shave reimbursement costs.